Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.29%
SPX
+0.02%
IXIC
+0.18%
FTSE
+0.35%
N225
+1.85%
AXJO
+0.43%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...
Join our newsletter to keep up to date with us!

Recently from Cashu

publisher logo
Cashu

REGENXBIO Launches Pivotal Trial for Gene Therapy in Diabetic Retinopathy

3 days ago
publisher logo
Cashu

Regenxbio: Navigating Mixed Analyst Sentiment in Gene Therapy Innovations

2 months ago
publisher logo
Cashu

RegenXBio's RGX-202 Shows Promise in Duchenne Muscular Dystrophy Gene Therapy Trial

2 months ago

Key Stats

Market Cap
393.76M
Dividend Yield
0.00%
P/E Ratio
-2.24
EPS
-4.60
Revenue
83.33M
Avg. Volume
636.71K

About

What does RGNX do?
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
Sector
💻 Health Care
IPO
CEO
Employees
353
Headquarters
Maryland, USA
Website
http://www.regenxbio.com
Stocks
Health Care
rgnx
Regenxbio
NASDAQ: RGNX
-0.23 (-2.93%)
7.62
USD
At close at Aug 11, 15:10 UTC
Summary
News
Signals
Benchmarks
Financials